Back to all assets

Sanofi SAN

equity

Price History

€38.29€60.33€82.36€104.4
1999-12 · DCA start€38.29

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-51.2%-34.1%-17.1%0.0%
1999-122026-08 · -27.5%

Worst drawdown: −51%, peaking Nov 2001 and bottoming Jan 2009 — 153 months below the prior high before recovering.

DCA Backtest

Invested
€32,100
Value today
€36,166
Return
+12.7%
Months invested
321

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be €43,119 today, so the real (inflation-adjusted) return is -16.1%.

Lump sum instead — €32,100 all at once in Dec 1999: €63,411 (+97.5%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Dec 2024): €1,901 on €2,100 invested (-9.5%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1999-12: +12.7%

About Sanofi

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. (Wikipedia)

It's a listed company categorised under health care.

It rates Medium-Low Risk at 1.9/5, meaning the rated factors are mostly sound, with one or two areas worth watching.

What pushes the score up: earnings quality (3.0/5) and sector / regulatory (3.0/5).

Scoring well: leverage / financial at 1.0/5.

Not yet researched: governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-Low Risk(1.9/5)90% rated

How these ratings work

Market / Volatility2.0/5 · weight 20%
  • Annualised volatility (3yr)2/519.6
  • Max drawdown from ATH3/551.2
  • Beta vs S&P 5001/5-0.05
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5152.6m
  • Float % of shares outstandingnot yet researched
Leverage / Financial1.0/5 · weight 20%
  • Debt / equity1/50.28
  • Interest coverage (EBIT / interest)1/510.9
Earnings Quality3.0/5 · weight 15%
  • 3yr EPS volatility3/529.6
Concentration2.0/5 · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentration2/5majority stable region
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.